In a bid to expand its presence in the rare disease segment, Alexion, AstraZeneca Rare Diseasehas agreed to acquire LogicBio Therapeutics. The deal, which is worth up to US$68.2 M, provides the rare disease specialist with access to LogicBio’s two platforms, GeneRide™ and sAVVy™, as well as multiple preclinical assets in the rare disease area. Interestingly, the deal came one month after AstraZeneca announced positive data fromits Phase III clinical trial, for the candidate ALXN2040 as an add-on drug for the patients with paroxysmal nocturnal haemoglobinuria.